Open Nav

Heidelberg Pharma AG

  • Jan Schmidt-Brand, Heidelberg Pharma AG

Update for investors

  • Date:Wednesday, October 17
  • Time:11:00 AM - 11:15 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Heidelberg Pharma is a publicly listed, biopharmaceutical company focused on oncology. It is the first company developing the toxin Amanitin into cancer therapies, using ist proprietary Antibody Targeted Amanitin Conjugates (ATAC) technology. In addition to collaborating with partners, Heidelberg Pharma is increasingly focused on developing its own ATAC candidates. Its lead ATAC product candidate HDP-101, is being developed for the treatment of mulitple myeloma using a BCMA (B-cell maturation antigen) antibody. HDP-101 has demonstrated strong efficacy and good tolerability in several animal models. A Phase I/IIa clinical trial with HDP-101 is planned to start by mid of 2019.
  • Company
  • Company HQ City:Ladenburg
  • Company HQ Country:Germany
  • Ticker:WL6
  • Exchange:Frankfurt
  • CEO/Top Company Official:Dr. Jan Schmidt-Brand
  • Year Founded:1999
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :HDP-101
  • Development Phase of Primary Product:Pre-Clinical
Jan Schmidt-Brand
Heidelberg Pharma AG